CVS Health Corp

CVS is in a Stage 2 advancing regime within a strong uptrend and parabolic acceleration phase. However, price is currently extended above rising short-term EMAs within extreme overbought territory, suggesting to wait for a pullback into the rising 9/20 EMA support zone before initiating new long entries.

• ↑Q1 revenue $100B, up 6% YoY across all segments
• ↑Adjusted EPS $2.57, +14% YoY; guide raised to $7.30–$7.50
• ↓P/E 44.97x vs 25.9x industry average, ~31% overvalued